Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population.
Type I IFN has been demonstrated to have major regulatory effects on the outcome of bacterial infections. To assess the effects of exogenously induced type I IFN on the outcome of Mycobacterium tuberculosis infection, we treated pathogen-exposed mice intranasally with polyinosinic-polycytidylic acid condensed with poly-l-lysine and carboxymethylcellulose (Poly-ICLC), an agent designed to stimulate prolonged, high-level production of type I IFN. Drug-treated, M. tuberculosis-infected WT mice, but not mice lacking IFN-alphabeta receptor 1 (IFNalphabetaR; also known as IFNAR1), displayed marked elevations in lung bacillary loads, accompanied by widespread pulmonary necrosis without detectable impairment of Th1 effector function. Importantly, lungs from Poly-ICLC-treated M. tuberculosis-infected mice exhibited a striking increase in CD11b+F4/80+Gr1int cells that displayed decreased MHC II expression and enhanced bacterial levels relative to the same subset of cells purified from infected, untreated controls. Moreover, both the Poly-ICLC-triggered pulmonary recruitment of the CD11b+F4/80+Gr1int population and the accompanying exacerbation of infection correlated with type I IFN-induced upregulation of the chemokine-encoding gene Ccl2 and were dependent on host expression of the chemokine receptor CCR2. The above findings suggest that Poly-ICLC treatment can detrimentally affect the outcome of M. tuberculosis infection, by promoting the accumulation of a permissive myeloid population in the lung. In addition, these data suggest that agents that stimulate type I IFN should be used with caution in patients exposed to this pathogen.
Antonelli
Lis R V
LR
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA. lisantonelli@cpqrr.fiocruz.br
Gigliotti Rothfuchs
Antonio
A
Gonçalves
Ricardo
R
Roffê
Ester
E
Cheever
Allen W
AW
Bafica
Andre
A
Salazar
Andres M
AM
Feng
Carl G
CG
Sher
Alan
A
D000281:Administration, Intranasal; D000818:Animals; D039481:CD11b Antigen / Q000096:biosynthesis; D002266:Carboxymethylcellulose Sodium / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D007370:Interferon Type I / Q000378:metabolism; D016899:Interferon-beta / Q000378:metabolism; D008168:Lung / Q000382:microbiology*; D008264:Macrophages / Q000166:cytology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000166:cytology*; D011070:Poly I-C / Q000627:therapeutic use*; D011107:Polylysine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054390:Receptors, CCR2 / Q000378:metabolism; D014376:Tuberculosis / Q000188:drug therapy*
D039481:CD11b Antigen; C515335:Ccr2 protein, mouse; D007370:Interferon Type I; D054390:Receptors, CCR2; D011107:Polylysine; D016899:Interferon-beta; C019531:poly ICLC; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C
J Immunol. 2008 Nov 1;181(9):6349-60
18941226
J Exp Med. 1997 Nov 17;186(10):1757-62
9362535
Cell. 2009 Jan 9;136(1):17-9
19135882
Arch Bronconeumol. 2008 Mar;44(3):173-4
18361890
J Immunol. 1981 Jun;126(6):2139-42
6164722
Nature. 1997 Dec 11;390(6660):629-32
9403695
Infect Immun. 1991 May;59(5):1857-9
2019446
Am J Respir Crit Care Med. 1998 Oct;158(4):1156-62
9769275
J Exp Med. 2009 Jul 6;206(7):1589-602
19564349
Nat Rev Drug Discov. 2007 Dec;6(12):975-90
18049472
Nat Immunol. 2006 Mar;7(3):311-7
16462739
Cancer Res. 2006 Jan 15;66(2):1123-31
16424049
J Interferon Cytokine Res. 2005 Nov;25(11):694-701
16318583
Immunity. 1995 Jun;2(6):561-72
7540941
J Immunol. 2002 Dec 1;169(11):6522-9
12444163
J Biol Chem. 2001 Aug 10;276(32):30178-82
11487589
J Immunol. 1985 Sep;135(3):1857-63
3926890
Blood. 2008 Apr 15;111(8):4233-44
18272812
Cell. 2009 Jan 9;136(1):37-49
19135887
J Exp Med. 2004 Aug 16;200(4):437-45
15302901
J Exp Med. 2005 May 2;201(9):1435-46
15851485
Immunity. 1998 Jan;8(1):77-87
9462513
Eur Cytokine Netw. 2000 Mar;11(1):99-104
10705306
Infect Immun. 1981 Nov;34(2):416-21
6171519
J Exp Med. 1993 Dec 1;178(6):2249-54
7504064
J Exp Med. 2004 Aug 16;200(4):535-40
15302900
Immunity. 2008 Aug 15;29(2):306-17
18691912
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):459-71
17703986
Immunity. 2007 Sep;27(3):505-17
17892853
J Exp Med. 1993 Dec 1;178(6):2243-7
8245795
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2574-9
18256187
Immunol Cell Biol. 2008 Jul;86(5):398-408
18392044
N Engl J Med. 2001 Oct 11;345(15):1098-104
11596589
Infect Immun. 1998 Sep;66(9):4491-5
9712805
J Infect Dis. 1975 Oct;132(4):434-9
810520
PLoS Pathog. 2009 Apr;5(4):e1000373
19360120
J Immunol. 2007 Jul 1;179(1):522-31
17579073
J Immunol. 2009 Jul 15;183(2):1301-12
19561100
Curr Opin Immunol. 2000 Aug;12(4):419-24
10899033
Ann Hepatol. 2008 Jan-Mar;7(1):87-90
18376374
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5752-7
11320211
Immunity. 2003 Jul;19(1):59-70
12871639
Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67
13465720
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7958-63
11438742
J Immunol. 1998 May 1;160(9):4298-304
9574532